Abstract

The Summary of Product Characteristics (SmPC) is an obligatory document concerning a medicine required (among other things) for the authorization of a medicinal product. The purpose of the SmPC is to provide product information to healthcare professionals. A necessary condition for this is to ensure that the SmPC is clear and precise. However, neither European nor national legislation obliges marketing authorization holders to review the SmPC in terms of its readability and understandability prior to the registration of a medicine. To date, research on SmPCs has focused on accuracy and completeness; however, the literature lacks information on the extent to which SmPCs meet the needs of healthcare professionals concerning the readability of the information they contain. The main objective of this article is to point out the lack of precision in the legal provisions for the preparation of SmPCs concerning the comprehensibility of the provisions. The article points to the lack of testing of the SmPC in terms of accessibility and transparency for healthcare professionals, highlighting that the document does not meet the needs of healthcare professionals in providing adequate information about medicines. It shows that the current rules and guidelines for the preparation of the registration dossier for a medicinal product are not entirely precise and contain numerous shortcomings.

Highlights

  • The Summary of Product Characteristics (SmPC) is a legal document, is one of the obligatory elements of the registration dossier of a medication, and is necessary to issue a marketing authorization for a medicinal product

  • This paper aims to identify gaps in the legislation and guidelines for the preparation of a medicinal product registration dossier

  • Understanding of the Information Contained in the SmPC

Read more

Summary

Introduction

The Summary of Product Characteristics (SmPC) is a legal document, is one of the obligatory elements of the registration dossier of a medication, and is necessary to issue a marketing authorization for a medicinal product. The obligation to draw up a Summary of Product Characteristics is laid down in several European Parliament laws. The first documents were Directive 2001/83/EC of the European Parliament and the Council relating to medicinal products for human use, and Regulation 726/2004. The document was amended several times and replaced in 2004 by Directive 2004/27/EC. The latest consolidated version of Regulation 726/2004 is dated 5 June 2013 [1,2].

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.